Acadia Pharmaceuticals has plans to combine Phase III CLARITY-2 and CLARITY-3 clinical trials of pimavanserin for the adjunctive therapy of major depressive disorder (MDD) into one study.

The announcement follows positive feedback from the US Food and Drug Administration (FDA). The combined study will involve a pre-specified statistical analysis plan.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Acadia noted that the trials will not enrol any new patients and each study will be concluded with approximately 50% enrollment. Top-line data from the combined study is expected in the third quarter of this year.

If the combined study yields positive results, along with the positive data from the previous pivotal CLARITY study, it is expected to support a supplemental new drug application for pimavanserin as the adjunctive treatment of MDD.

Pimavanserin is a selective serotonin inverse agonist and antagonist that preferentially targets 5-HT2A receptors, which are thought to be involved in psychosis, schizophrenia, depression, and other neuropsychiatric disorders.

Both CLARITY-2 and CLARITY-3 are six-week, parallel-designed, randomised, double-blind, placebo-controlled, multi-centre trials assessing the safety and efficacy of pimavanserin as adjunctive treatment for MDD.

The trials enrolled patients who have had an inadequate response to standard antidepressant therapy. Primary endpoint of the trials is the change from baseline on the 17-item Hamilton Depression Rating Scale (HAMD-17) total score.

Participants who completed the Phase III trials were eligible for an ongoing 52-week open-label extension study, which evaluates the long-term safety and tolerability of the drug in MDD patients.

Acadia said that the open-label extension study is ongoing as per the plan.

In December last year, the company reported that pimavanserin decreased the risk of psychosis relapse in dementia patients who participated in its Phase III HARMONY trial.